ARALAST NP

For individuals with alpha-1-proteinase inhibitor deficiency, this medication is utilized to address lung issues (emphysema) that arise due to the damage caused by elastase, a natural substance required by the body to eliminate bacteria in the lungs.

If both of your parents pass on a mutated or changed AAT gene to you, you will have AAT deficiency. However, if only one parent passes on a mutated AAT gene and the other parent passes on a normal AAT gene, you will be a carrier for the condition.

This medication is intended for intravenous use only. The recommended dose of Aralast® is 60 mg per kilogram of body weight, to be administered once weekly through intravenous infusion. The functional activity of each vial of Aralast®, as determined by its ability to inhibit porcine pancreatic elastase, is clearly indicated on the label.

GLASSIA allows you to have control over your infusion experience. You can choose to receive your infusion at an outpatient infusion center, at home with a healthcare provider, or at home through self-infusion or with the help of a caregiver, as long as you have received the necessary training.

To ensure safe administration, it is important to keep the pooled solution at room temperature and use it within 3 hours. Prolastin-C Liquid should not be mixed with any other agent or solution. Additionally, a sterile 15 micron in-line filter should be used when administering the product.

Glassia is a trademark owned by Kamada Ltd. and is used under license.

To treat Alpha-1, it is recommended to administer ZEMAIRA intravenously once weekly at a dose of 60 mg/kg of body weight.

The Pentoxil M 0.5mg/10mg Tablet offers the benefit of preventing drastic mood changes and reducing agitation. It can also decrease the frequency of depression episodes and low moods. However, it may take a few weeks for the medication to take effect, so you may still experience low moods during this time.

The tablet is available for the management of various conditions including anxiety, depression, apathy, psychogenic depression, depressive neuroses, masked depression, psychosomatic affections accompanied by anxiety and apathy, menopausal depressions, dysphoria, and depression in alcoholics and drug addicts.

Producer: Baxalta US Inc.

Aralast (alpha 1-proteinase inhibitor), Prolastin-C (alpha 1-proteinase inhibitor), Aralast NP, Glassia, Zemaira

Glassia is the initial liquid augmentation therapy for severe Alpha-1 Antitrypsin Deficiency with Emphysema that has been approved by the FDA.

Grifols is a renowned manufacturer that specializes in producing PROLASTIN-C Liquid.

Glassia is a registered trademark of Kamada Ltd., and it is being used under license. Shire and Baxalta are trademarks of Shire plc, its subsidiaries, or affiliates.

1 unit at $10.14 each, for a total of $10.14

Aralast NP is administered to patients intravenously, with treatment time typically lasting approximately 15 minutes at medical clinics such as IVX Health.

Range Used in Sensitivity Analyses

Variable
Base Case Estimate
High

Annual cost of augmentation therapy
$54,765
$109,530

Annual cost of Stage I COPD
$1,966
$3,932

Annual cost of Stage II COPD
$5,892
$11,784

Brukinsa (zanubrutinib) belongs to the BTK inhibitors drug category and is frequently prescribed for conditions such as Chronic Lymphocytic Leukemia, Lymphoma, Mantle Cell Lymphoma, and others. The price of Brukinsa oral capsule 80 mg is approximately $15,264 for a 120-capsule supply, varying depending on the pharmacy you choose.

ARALAST NP is produced by utilizing the cold ethanol fractionation method on extensive human plasma pools. This is then followed by purification procedures involving polyethylene glycol and zinc chloride precipitations, as well as ion exchange chromatography.

Flutamide, also known by its brand name Eulexin, is a medication belonging to the antiandrogens drug class. It is commonly prescribed for the treatment of Hirsutism and Prostate Cancer. The cost of flutamide oral capsule 125 mg can vary depending on the pharmacy, but it is typically around $774 for a supply of 180 capsules.

Quantity: 30
Unit Price: $89.82
Total Price: $2,694.72

Quantity: 180
Unit Price: $89.57
Total Price: $16,123.09

Alpha-1 proteinase inhibitor injection, also known as alpha 1-PI, is administered to patients with a specific form of emphysema, a respiratory condition. This particular type of emphysema is characterized by a deficiency of alpha 1-antitrypsin (AAT) protein in the body. The medication serves to supplement the lacking protein in cases where the body fails to produce an adequate amount.

Austedo Prices, Coupons, and Patient Assistance Programs: Austedo (deutetrabenazine) belongs to the VMAT2 inhibitors drug class and is frequently prescribed for Huntington’s Disease and Tardive Dyskinesia. The price of Austedo oral tablet 6 mg is approximately $4,980 for a 60-tablet supply, varying depending on the pharmacy you choose.

Based on the results, Zemaira had the highest specific activity among the three products. The RP-HPLC analysis showed that Zemaira had an average purity of 99%, while Aralast had 70% purity and Prolastin had less than 62% purity. Additionally, using SEC-HPLC, Zemaira was found to be 95.98% monomeric, Prolastin was 79.00% monomeric, and Aralast was 63.55% monomeric. Furthermore, Prolastin had a lower activity per milligram of antigenic A1-PI compared to the other two products.

Symptoms include headache, muscle and joint discomfort, bruising at the injection site, nausea, fatigue, and a runny nose.

Administration of ARALAST NP should be done at a maximum rate of 0.2 mL per kg body weight per minute, based on patient response and comfort. If any adverse reactions occur, the infusion rate should be decreased or stopped. Once symptoms have subsided, the infusion can be resumed at a rate that the patient can tolerate.

Aralast should be used on its own and should not be mixed with other substances or diluted. There have been no studies conducted on animal reproduction with Aralast.

In terms of biochemical efficacy, Glassia was found to be comparable to Prolastin based on plasma antigenic and functional (ANEC) A1PI trough levels at steady state. The results, with a geometric mean ratio (GMR) near or above 100%, support the original findings of the study that Glassia is non-inferior to Prolastin.

Zemaira is a sterile, white, freeze-dried preparation of purified Alpha1-Proteinase Inhibitor (Human) (A1-PI), also referred to as alpha1-antitrypsin. It is intended to be reconstituted and given intravenously.

ZEMAIRA should be given intravenously at a rate of around 0.08 mL/kg/min, based on the patient’s response and comfort. The suggested dose of 60 mg/kg body weight will require roughly 15 minutes to administer.

For individuals with alpha-1-proteinase inhibitor deficiency, this medication is utilized to address lung issues (emphysema) that arise due to the damage caused by elastase, a natural substance required by the body to eliminate bacteria in the lungs.